Bionano uses a unique high-throughput optical mapping technology to detect structural variants. This unique approach provides us with exceptional performance, but this difference can make our first contact with scientists who don’t know Bionano complicated.
That’s why we put together a white paper that describes why SVs matter in cancer and genetic disease, and how Bionano can detect structural variants with much higher sensitivity and lower false positive rates than any other technology out there. The paper also shows some impressive examples of published and yet unpublished variants of clinical significance.
We just updated this white paper to discuss all the performance improvements the DLS labeling chemistry brings.
